Workstream Goes Reverse Stock Split

by admin on May 8, 2011

Workstream (OTCBB:WSTM – News), a leading provider of human capital management software and services, announced today that its Board of Directors has approved a one-for-four hundred reverse stock split of Workstream common stock. The company anticipates the stock split will be effective after the close of business May 6, 2011. Workstream stockholders had authorized the Board of Directors to approve a reverse stock split at a ratio of between one-for-two hundred and one-for-four hundred at the company’s April 29, 2011 Annual Shareholder’s Meeting.

When the reverse stock split becomes effective, every four hundred shares of issued and outstanding Workstream common stock will automatically be combined into one issued and outstanding share of common stock without any change in the par value of the shares. The number of authorized shares of the company’s common stock will also be proportionately reduced from 992,094,055 to 2,480,235.

No fractional share will be issued in connection with the reverse stock split. Stockholders who would otherwise hold a fractional share of the company’s common stock will receive a cash payment in lieu of such fractional share based upon the average closing bid prices of our common shares during each of the five traded days preceding the effective date of the reverse stock split.

About Workstream: Workstream provides a variety of solutions for recruitment, compensation planning, performance management, and talent management solutions and services that help companies manage the employee lifecycle. Workstream’s Talent Center enables employers to align their talent strategy with their business strategy. Solutions are offered as Software as a Service (SaaS.)

{ 0 comments }


Advanced Cell Technology, a small Massachusetts-based biotechnology company that has struggled to bring human embryonic stem cells from the lab to the clinic, will begin recruiting 12 patients in Oregon and Massachusetts with a rare eye condition called Stargardt’s macular dystrophy.

What macular degeneration is? Due to this disease, the cells at the center part of your eye(Which is critical for focus) dies. As a result the patient becomes blind or near blind. If successfull, Advanced Cell technologies new research could brighten the lives of many.  

This is the most immediate promise of human embryonic stem cell research — that these immature cells can be coaxed partly down the road to becoming a desired tissue type, and in the process get other cells growing and renewing.

Advanced Cell Technology’s product is a human embryonic stem cell trained to become a retinal cell. For this first clinical trial, only a few thousand of these cells will be injected into one eye of each volunteer, mostly to check to see that it is safe.

ACT’s Dr. Robert Lanza says the doctors taking part in the trial will be able to watch it unfolding in real-time, because it is possible to look into the eye and see the cells taking up residence in the retina. And it will be possible to continuously check the vision of the patients, to see if it is improving.

Stargardt’s affects only 30,000 to 50,000 Americans, according to the American Macular Degeneration Foundation, but ACT has its sights set on a much larger market if this trial is successful — age-related macular degeneration.

This blinding condition affects more than 30 million people worldwide and is the leading cause of blindness in people over 60 in the United States. Many will be praying for the success of this clinical trial, as it can literarly brighten the lives of many thousnads in the world.

This fresh news caused the share to jump near 50%.  Currently shares are traded at .07 (7cents) per share.  It makes sense to invest in this as a couple of hundred dollers can buy you about 3000 shares. For an investor,  the success of this trial will give good returns in long term.  ACTC has around 958 million Shares Outstanding.

Advanced Cell Technology, Inc., a biotechnology company, focuses on the development and commercialization of human embryonic and adult stem cell technology in the field of regenerative medicine. It primarily focuses on cellular reprogramming, reduced complexity program, and stem cell differentiation research programs. The company’s cellular reprogramming involves in the development of therapies based on the use of genetically identical pluripotent stem cells generated by its cellular reprogramming technologies. Advanced Cell Technology, Inc. is also generating stable cell lines with particular focus on blood lineage and vascular epithelial cell lines from hemangioblast cells. In addition, it is developing an autologous myoblast transplantation therapy to restore cardiac function in patients with advanced heart disease. The company’s stem cell-based therapy would provide treatment for a range of acute and chronic degenerative diseases. Further, it develops adult stem cell-based products that are specifically targeted at therapies for heart and other cardiovascular diseases. The company is headquartered in Worcester, Massachusetts.

{ 0 comments }


What is in Store for Generex Biotechnology Corporation

September 21, 2010

Generex Biotechnology Corporation, a development stage company, engages in the research, development, and commercialization of drug delivery systems and technologies for metabolic and immunological diseases. It develops a proprietary platform technology for the oral administration of large molecule drugs, including proteins, peptides, monoclonal antibodies, hormones, and vaccines. The company’s products include Generex Oral-lyn, an insulin [...]

Read the full article →

One World Ventures Fuels Expansion

August 17, 2010

One World Ventures, Inc. (Pinksheets:OWVI) announced on 08/13/2010 that, it has successfully obtained funding to further expand the business operations in its effort to become more profitable and provide greater shareholder value. One World had increased the authorized shares by 500 million and was able to successfully place shares which will enable the company to [...]

Read the full article →

Stock Dips as Workstream Inc. Announces Major Expansion Plans

August 16, 2010

MAITLAND, Fla., Aug. 16, 2010 (GLOBE NEWSWIRE) — Workstream Inc. (OTCBB:WSTM ) today announced expansion of its management, appointment of a new Board of Directors, new capital structure and additional capital for the human capital technology, software and services company. The changes are expected to result in growth of the business and the introduction of additional [...]

Read the full article →

Hot Penny Stocks to Invest

June 20, 2010

One of my preferred straightforward investing strategies for individual investors is to put your retirement funds in a increasing stock. That sounds pretty simple, but many traders fast understand it’s not as simple an investment strategy as it looks — especially while it comes to finding hot penny stocks to buy now. After all, many [...]

Read the full article →

Guide of Cord Blood America

April 18, 2010

More than 8000 transplants has been done using Cord Blood since the first transplant in 1988.Families know that there is only one opportunity – at birth – to collect these genetically unique stem cells and if not taken, the cord blood is simply discarded.This technology to collect and store newborn’s umbilical cord blood stem cells [...]

Read the full article →

Alternate Job Income System

April 12, 2010

Is it possible for you to make money working online in your spare time using your home computer. Many of these online money making is not requiring any series investing, and no need to have a product or sales and marketing skills. This is a full time and a part time job opportunity for any [...]

Read the full article →

Review of Work from Home System

April 11, 2010

Is it possible for you to make money working online in your spare time. Many of these online money making is not requiring any series investing, and no need to have a product or sales and marketing skills. Why one prefers online job compared to traditional job? They are: Very flexible timing as you are [...]

Read the full article →